Related Experiment Video
Updated: Jul 10, 2026

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Inhaled nitric oxide in the management of preterm infants with severe respiratory failure
1Department of Pediatrics, Division of Neonatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Insights
Inhaled nitric oxide (iNO) improved oxygenation in preterm infants with severe respiratory distress syndrome (RDS). However, iNO did not significantly reduce mortality or long-term complications like chronic lung disease.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Critical Care Medicine
Background:
- Severe respiratory distress syndrome (RDS) in preterm infants often involves high pulmonary vascular resistance and poor ventilation-perfusion matching.
- Inhaled nitric oxide (iNO) is known to improve gas exchange and decrease pulmonary vascular resistance.
Purpose of the Study:
- To evaluate the efficacy of inhaled nitric oxide (iNO) therapy in improving oxygenation in preterm infants suffering from severe RDS and respiratory failure.
- To assess potential short-term side effects of iNO therapy in this vulnerable population.
Main Methods:
- A randomized study involving 65 preterm infants (birth weight <1500g, gestational age <31 weeks) with severe RDS and respiratory failure (Oxygenation Index [OI] ≥25).
- Infants were randomly assigned to receive either iNO therapy (starting at 5 ppm, max 20 ppm) or a placebo (inhaled oxygen).
- The study was randomized but not blinded, with management by neonatologists independent of data analysis.
Main Results:
- The iNO therapy group demonstrated a significantly lower OI compared to the control group at multiple time points (30 min, 3, 12, and 24 hours) post-initiation (P<0.01).
- Mortality rates were 6/32 in the iNO group and 10/33 in the control group.
- No significant differences were observed in the incidences of chronic lung disease (CLD), intracranial hemorrhage (ICH), patent ductus arteriosus (PDA), retinopathy of prematurity (ROP), or duration of intubation between groups.
Conclusions:
- iNO therapy effectively improves oxygenation in preterm infants with severe RDS and respiratory failure.
- The therapy was not associated with significant short-term adverse effects.
- iNO therapy did not demonstrate a significant reduction in mortality rates or the incidence of major morbidities including CLD, ICH, PDA, or ROP.
Objective:
Elevated pulmonary vascular resistance and poor ventilation-perfusion matching are commonly found in preterm infants with severe respiratory distress syndrome (RDS) and respiratory failure. Inhaled nitric oxide (iNO) can improve gas exchange and decrease pulmonary vascular resistance. This study was conducted to determine whether iNO therapy improves oxygenation in such infants.
Study Design:
Between July 2000 and 2006, 65 preterm infants (birth weight, <1500 g; gestational age, <31 weeks) with severe RDS and respiratory failure requiring mechanical ventilation and an oxygenation index (OI)>or=25 were randomly divided into two groups. Group A infants (n=32) received iNO therapy. iNO was started at a dose of five parts per million (p.p.m.). The maximal dose of NO was 20 p.p.m. Group B infants (n=33) did not receive iNO therapy, receive inhaled oxygen placebo only, was served as control group. Mechanical ventilation and iNO therapy were managed by neonatologists who were not involved in safety monitoring, data analysis and interpretation, or manuscript preparation. This study was randomized but not blinded.
Result:
The OI was significantly lower (P<0.01) in the iNO therapy group than in the control group at 30 min, 3, 12 and 24 h after initiating iNO therapy. Six infants in the iNO-treated group and 10 infants in the control group died. Post hoc analyses did not reveal any significant differences in the incidences of chronic lung disease (CLD), intracranial hemorrhage (ICH), patent ductus arteriosus (PDA), retinopathy of prematurity (ROP) or duration of intubation between the iNO-treated and the control groups.
Conclusion:
We conclude that iNO therapy leads to an improvement in oxygenation without short-term side effects (such as pulmonary hemorrhage, intracranial hemorrhage, pneumothorax or acute deterioration) in premature infants with severe RDS and respiratory failure. However, iNO therapy does not significantly reduce mortality rate or the incidences of CLD, ICH, PDA or ROP.
Related Concept Videos
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation (NIPPV)
Endotracheal Intubation I: Procedure
The ET tube comprises various components, including a standard adaptor to attach a bag-valve-mask (BVM) or ventilator, a cuff, a pilot balloon, and radiopaque markings along its length to measure the insertion distance. The tube sizes...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Cardiopulmonary Resuscitation II: ACLS Airway Management

